Futuremeds Spain S.L.

Running trials

• Recruiting

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· Phase 3· Source

• Not yet recruiting

  Study of a DPP 4 inhibitor and an SGLT2 inhibitor used together compared with each treatment alone in adults with type 2 diabetes treated with metformin.

  2025-524606-15-00· Phase 3· Source

• Active, not recruiting

  Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

  NCT07486960· Phase 2· Source

• Recruiting

  A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

  NCT07456033· Phase 3· Source

• Not yet recruiting

  A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)

  2025-522471-28-00· Phase 3· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

  NCT07400653· Phase 3· Source

• Active, not recruiting

  Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  NCT07284901· Phase 3· Source

• Recruiting

  Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)

  2025-521562-95-00· Phase 3· Source

• Active, not recruiting

  Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

  NCT07311850· Phase 3· Source

• Active, not recruiting

  Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  NCT07284875· Phase 3· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

  2024-516652-18-00· Phase 3· Source

• Recruiting

  Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  NCT07116967· Phase 3· Source

• Recruiting

  Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

  NCT07120503· Phase 2· Source

• Recruiting

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

  NCT07037901· Phase 2· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

  NCT06958536· Phase 2· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs

  2024-516213-20-00· Phase 3· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.

  2024-516219-25-00· Phase 3· Source

• Active, not recruiting

  A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

  NCT06748053· Phase 2· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

  NCT06617325· Phase 3· Source

• Active, not recruiting

  Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

  NCT06676319· Phase 2· Source

• Active, not recruiting

  A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus

  2024-510584-37-00· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

  NCT06625060· Phase 2· Source

• Enrolling by invitation

  Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

  NCT06609239· Phase 2· Source

• Enrolling by invitation

  A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

  NCT04976322· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma3 recruiting
• Lupus (SLE)2 recruiting
• Psoriasis2 recruiting
• Psoriatic arthritis2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Crohn's disease1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Obesity1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis

  NCT06073093· Phase 2· Source